Skip to main content
. 2018 Jun 12;2(11):1356–1366. doi: 10.1182/bloodadvances.2018016378

Table 4.

Testing technologies and potential markers for monitoring MRD in AML

Testing technologies Potential markers
MFC CD2 CD34
CD4 CD45
CD7 CD56
CD13 CD123
CD15 CD117
CD19 HLA-DR
CD33
NGS NPM1
RUNX1
FLT3-ITD
IDH1/IDH2
RT-qPCR CBFB/MYH11
FLT3-ITD
IDH1/IDH2
NPM1
RUNX1/RUNX1T1
t(10;11) – KMT2A-MLLT10
t(11;19) – KMT2A-ELL or KMT2A-MLLT1
t(6;11) – KMT2A-MLLT4
t(9;11) – KMT2A-MLLT3
WT1

MLL/MLLT3, mixed lineage leukemia.